Abstract:
A sterile method for preparing stable thrombin component from a single donor&#39;s plasma in which the thrombin component is harvested simultaneously from the clotting and adhesive proteins component from the same donor plasma in less than one hour. The combined components provide an improved biological hemostatic agent and tissue sealant by virtue of its freedom from the risk of contaminating viruses or bacteria from allogenic human or bovine blood sources. The thrombin provides polymerization of the clotting and adhesive proteins in less than five seconds, and is sufficiently stable to provide that fast clotting over a six hour period. Further, the clotting times can be predictably lengthened by diluting the thrombin with saline.

Description:
FIELD OF THE INVENTION 
     The following invention relates generally to the preparation of thrombin enzyme from a given unit of plasma, which is sufficiently stable that it provides rapid clotting of a fibrinogen-rich solution of clotting and adhesive proteins for more than six hours. 
     BACKGROUND OF THE INVENTION 
     Formulation of a fibrin sealant mimics the last step of the coagulation cascade wherein the enzyme thrombin cleaves fibrinogen which is then cross-linked into a semi-rigid or flexible fibrin clot. This fibrin clot adheres to wound sites, forming a barrier to fluid leaks and generates adhesion between tissues, while providing hemostatic and healing properties to the treated site. 
     Presently marketed, applicant&#39;s CryoSeal™ system is a device which harvests cryoprecipitated, concentrated clotting and adhesive proteins, including fibrinogen and Factor XIII from a donor&#39;s plasma in approximately one hour. The one hour cryoprecipitation harvesting, provided by the CryoSealT system, compared to the 1 to 2 day cryoprecipitation process routinely practiced in Blood Banks, means that CryoSeal™ harvesting of clotting and adhesive proteins can occur right in the perioperative theater with the patient close by, thereby avoiding the need to initiate the process days in advance. 
     These CryoSeal™ harvested clotting and adhesive proteins, when combined with bovine or human thrombin, forms a biological glue useful for surgical hemostasis and tissue adhesion. Commercially available thrombin, however, is generally sourced from bovine or human plasma pools, so the patient would still be at risk of negative immune reactions or contamination by infectious blood born viruses and, possibly Crutzfeld-Jacobs Disease (CJD) or new variants of CJD (NVCJD). An advantage of the CryoSeal™ cryoprecipitation invention is that the harvested clotting and adhesive proteins sourced from the patient&#39;s own blood eliminates the risk of contamination by infectious blood-borne disease when these clotting and adhesive proteins are topically applied to the patient&#39;s surgical wound sites. 
     It has long been understood, however, that the safest condition for a surgical patient would result from a two component biological sealant preparation in which the thrombin component would be harvested from the same donor in which the clotting and adhesive protein component was harvested—forming a fully autologous biological sealant or glue. 
     For instance, Cederholm-Williams PCT Patent (WO94/00566-Jan. 6 1994) clearly describes an improved fibrin glue in which the thrombin component whose preparation method,—adjusting the ionic strength of the blood and pH of the plasma to cause precipitation of a thrombin component for later resolubalization was described therein, would be combined with a fibrinogen component also sourced from the plasma of the same donor. These steps are so time consuming they become impractical for use in the perioperative theater where processing times should be less than one hour. 
     Three years later, in 1997, Hirsh, et al. (U.S. Pat. No. 5,643,192) follows the lead of Cederholm-Williams by also teaching a method of preparing fibrin glue in which both the fibrinogen and thrombin components of a fibrin glue are sourced from the same donor&#39;s plasma. The Hirsh patent describes a method of preparing thrombin in which the fibrinogen in the plasma is first precipitated to prepare a supernatant and then clotting the residual fibrinogen in the supernatant which is different than the method taught by Cederholm-Williams, but does not result in a commercially useful thrombin in that (see figure 1 of Hirsh, et al.) the thrombin provides clotting speeds of five seconds or less for only 4 minutes, and less than 10 seconds for only 47 minutes. 
     These clotting speeds are unsuitable to the needs of surgeons who could not plan their entire surgeries around the limitations of the Hirsh, et al. fibrin glue. 
     Surgeons predominately require a fast acting clotting time (&lt;5 seconds) for hemostasis and tissue sealing or adhesion. Slow clotting biological glues (&gt;5 seconds) will often be transported away from the wound site by oozing and bleeding before they can perform their function. A surgeon utilizing the Hirsh fibrin glue would be required to arrange his surgery so that the hemostasis and tissue sealing intended for treatment with the Hirsh fibrin glue would occur within the 4 minute window where the clotting time was less than 5 seconds, making the Hirsh invention totally impractical for most surgeries which predominantly require rapid hemostasis and tissue adhesion throughout the surgery, the time span of which could extend to six hours. 
     The following prior art reflects the state of the art of which applicant is aware and is included herewith to discharge applicant&#39;s acknowledged duty to disclose relevant prior art. It is stipulated, however, that none of these references teach singly nor render obvious when considered in any conceivable combination the nexus of the instant invention as disclosed in greater detail hereinafter and as particularly claimed. 
     
       
         
               
             
               
               
               
             
               
             
               
               
               
             
           
               
                   
               
             
             
               
                 U.S. PATENT DOCUMENTS 
               
             
          
           
               
                 U.S. PAT NO. 
                 ISSUE DATE 
                 INVENTOR 
               
               
                   
               
               
                 5,648,265 
                 July 15, 1997 
                 Epstein 
               
               
                 5,510,102 
                 April 4, 1996 
                 Cochrum 
               
               
                 5,585,007 
                 December 17, 1996 
                 Antanavich, et al. 
               
               
                 5,605,887 
                 February 25, 1997 
                 Pines, et al. 
               
               
                 5,614,204 
                 March 25, 1997 
                 Cochrum 
               
               
                 5,631,019 
                 May 20, 1997 
                 Marx 
               
               
                 5,643,192 
                 July 1, 1997 
                 Hirsh, et al. 
               
               
                   
               
             
          
           
               
                 FOREIGN PATENT DOCUMENTS 
               
             
          
           
               
                 PATENT NO. 
                 ISSUE DATE 
                 INVENTOR 
               
               
                   
               
               
                 WO 94/00566 
                 January 6, 1994 
                 Cederholm-Williams, et al. 
               
               
                 EU 0 592 242 A1 
                 April 13, 1994 
                 E. R. Squibb &amp; Sons 
               
               
                   
               
             
          
         
       
     
     The other prior art listed above, not all of which are specifically discussed catalog the prior art of which the applicant is aware. These undiscussed references diverge even more starkly from the instant invention specifically distinguished below. 
     SUMMARY OF THE INVENTION 
     The instant invention addresses the long felt need for a simple, practical, fast method of preparing stable human thrombin from a donor&#39;s blood, which will provide fast clots (&lt;5 seconds) throughout a lengthy surgery (e.g. six hours) to combine with the clotting and adhesive proteins harvested and concentrated from the same unit of blood to form a biological sealant with no patient exposure to microbial or possible CJD or NVCJD contaminations. Previous works in the field (Hirsch, et al.) exemplified a thrombin with minimal stability in that the thrombin achieved rapid clotting of fibrinogen (i.e., less than 5 seconds) during only a very narrow four to five minute time period, totally impractical for the broad range of surgeries. 
     The present invention provides a stable thrombin enzyme which can cause precise, repeatable fast or slow polymerization of clotting and adhesive proteins over a duration of up to six hours—throughout even a long surgery. Further, the use of clotting and adhesive proteins and thrombin all sourced from a single donor will eliminate various disease risks posed from the use of commercial fibrin glues where the fibrinogen is sourced from plasma pooled from thousands of donors and the thrombin is either sourced from a similar pool of human plasma or of bovine origin. The speed and simplicity of the production of stable thrombin by use of this invention allows it to be prepared just prior to or during operative procedures and it will provide fast clotting throughout even the longest surgeries. The thrombin produced by this invention can be diluted in saline to provide precise, slower clotting times thereby allowing any preferred time from less than four seconds to longer than 2 minutes. 
     The procedure of the invention is comprised of three steps, the first two of which should occur at the same time: 
     1. Preparing a fraction enriched in prothrombin by use of Ethanol to substantially enhance the concentration of prothrombin and at the same time remove or denature naturally occurring ingredients within plasma, such as Thrombinodulin and Antithrombin III which can bind to, block, interfere with or inhibit prothrombin or its subsequent activation to long-term functional thrombin. 
     2. Adding calcium ions to the enriched prothrombin solution and briefly agitating the solution to convert the pro-thrombin to stable, long term thrombin. 
     3. Expressing the thrombin solution through a filter to remove particulate matter which would prevent spraying the thrombin through a small orifice or expressing the thrombin through a thin tube onto a wound site. 
     OBJECTS OF THE INVENTION 
     Accordingly, it is a primary object of the present invention to provide a new and novel apparatus and method to derive fast acting, stable autologous thrombin from the donor&#39;s plasma. 
     It is a further object of the present invention to provide thrombin as characterized above which has a shelf life longer than most associated surgical procedures. 
     It is a further object of the present invention to provide thrombin as characterized above in which the clotting time can be predictably lengthened at will through dilution with saline. 
     It is a further object of the present invention to provide thrombin as characterized above which has simple preparatory procedures. 
     It is a further object of the present invention to provide a method for producing thrombin as characterized above which has a process time of less than thirty minutes. 
     It is a further object of the present invention to provide thrombin which can be sprayed through small orifices or expressed through thin tubes. 
     Viewed from a first vantage point it is the object of the present invention to provide a novel and practical method for producing stable human thrombin from a prothrombin fraction which has been substantially enriched by ethanol fractionation to increase the prothrombin concentration and at the same time remove contaminating proteins. The addition of calcium chloride to the enriched prothrombin converts prothrombin to thrombin. From the same sole donor plasma, clotting and adhesive proteins are simultaneously obtained by other means to comprise the second component necessary for the autologous biological sealant. 
     The present invention provides a method and apparatus that produces thrombin which is sufficiently stable that it can provide less-than-5-second clots for up to six hours, substantially more stable than demonstrated in all prior art. Further, the clot time can be modified at will through dilution with saline. 
     The present invention further provides an efficient method of preparation. Improved cryoprecipitation of clotting and adhesive proteins through the CryoSeal™ invention requires less than one hour. In this same time frame, the autologous human thrombin component can be manufactured with minimal materials and methods from the same source plasma. Both of the biological components of the biological glue are easily combined in a surgical setting, administered to the very same donor patient, and the resultant clotting provides hemostasis or tissue adhesion at the wound site. 
     The present invention additionally provides a method for sterile production of both components of the biological glue. The improved sterile manufacturing described herein provides a final product that is essentially free of contamination by non autologous microbes. 
     These and other objects will be made manifest when considering the following detailed specification when taken in conjunction with the appended drawing figures. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS 
     FIG. 1 is a perspective view of an apparatus for sequestering prothrombin from plasma, processing the prothrombin into thrombin and taking the plasma not relegated towards the prothrombin and extracting clotting and adhesive proteins therefrom. 
     FIG. 2 is a sectional view of the thrombin processing unit where plasma is being admitted into a mixing syringe. 
     FIG. 3 is a view similar to FIG. 2 in which the processing reagents are directed to the mixing syringe for processing the plasma into prothrombin and then thrombin. 
     FIG. 4 is a view similar to FIGS. 2 and 3 where the thrombin is directed to a dispensing syringe after have first been filtered for particulate matter which could interfere with the thrombin being sprayed through a small orifice or expressed through a thin tube. 
     FIG. 5 is a chart illustrating the effect of various ETOH concentrations in the final volume on the life span of fast clotting thrombin when the CaCl 2  is held constant at 0.023 μm. 
     FIG. 6 is a chart illustrating the effect of various CaCl 2  concentrations in the final volume on the life span of fast clotting thrombin when the ETOH concentration is held constant at 13.6%. 
     FIG. 7 is a chart illustrating that the processing of the thrombin should occur in a glass syringe for a fast clotting preparation. 
     FIG. 8 is a chart describing the contaminating proteins removed from the enriched thrombin fraction after mixture with ETOH, (13.6% in final volume) and CaCl 2  (0.023 μm in final volume) and filtered for particulate matter. 
     FIG. 9 is a view showing the life span of optimized thrombin preparation for fast clotting. 
     FIG. 10 is a view showing the life span of optimized thrombin preparation diluted at 1:15 with sterile saline for slow clotting. 
     FIG. 11 is a chart illustrating the conversion/activation period required for the enrichment of a prothrombin fraction and its conversion to stable thrombin by mixture with a precise solution of ETOH and CaCl 2 . 
     FIG. 12 is a chart illustrating thrombin (Bovine) concentrations (activity) as it relates to speed of clotting. 
    
    
     DESCRIPTION OF PREFERRED EMBODIMENTS 
     Referring to the drawings, wherein like elements denote like parts throughout, reference numeral  10  is directed to the processing set according to the present invention and shown in FIG.  1 . 
     In its essence, the processing set  10  includes a fluid receiving system  20  which communicates with both a thrombin processing unit  40  and a clotting and adhesive proteins processing unit  60 . 
     More particularly, the fluid receiving system  20  includes an inlet  2  communicating with tubing  4  through which plasma will enter the processing units  40 ,  60 . The conduit  4  has a stop valve  6  which can occlude the tubing  4  preventing fluid&#39;s through passage. The tubing  4  communicates through a T fitting  8  to divide plasma into two branches, a first branch  12  which leads to the thrombin processing unit  40  and a second branch  14  leading to the clotting and adhesive proteins processing unit  60 . 
     Since it is preferred that the blood product admitted to the inlet  2  be plasma, the whole blood is first processed either by filtering, centrifugation, or another means of settling to remove the heavier red blood cells from the blood products, leaving plasma there beyond for use in the FIG. 1 device. The plasma required for the thrombin processing unit is preferably 8 ml. so that the final volume of concentrated thrombin matches a typical yield of cryoprecipitated clotting and adhesive proteins from the clotting and adhesive proteins processing unit  60 . Referring to FIG. 2, a sealed bag  16  overlies the thrombin processing unit  40  to provide sterility until the thrombin storage syringe is introduced into a sterile surgical field. Prior to that, the thrombin processing unit is operated as shown in FIG. 2 within the sealed bag which is flexible and sized to preferably permit the movement of the syringes′ plungers from the exterior of the bag. Fluid from the first branch  12  passes beyond a coupling  18  and into a manifold  22 . The manifold  22  is equipped with a valve  24  that initially is directed to a mixing syringe  26  preferably formed from glass and capable of receiving a volume as great as 15 ml. The mixing syringe  26  includes a plunger  28 , which when moved in the direction of the arrow A, draws the plasma from the passageway  12  and into the interior of the mixing syringe  26 . 
     Referring to FIG. 3, the valve  24  is reoriented so that access can be gained between the mixing syringe  26  and the reagents found in ampoules  32 ,  34 , each of which are operatively connected to the manifold  22  via a Y coupling  36  shown in FIG.  1 . Access to the interior of either ampoule  32  or  34  can be had by squeezing the ampoule to rupture a frangible diaphragm. Alternatively, the intake  38  which receives the ampoule can be provided with a hollow spike which penetrates the diaphragm. In either event, the contents of both of the ampoules  32 ,  34  are received in the mixing syringe  26  by further retraction of the plunger  28  along the arrow A a shown in FIG. 3. A first ampoule  32  is preferably provided with 2 ml. of ethanol providing an ETOH concentration in the final volume of 13.6% and the second ampoule  34  is preferably provided with 1 ml. calcium chloride providing a concentration in the final volume of 0.023 μm. Alternatively, these reagents contained within the two ampoules  32 ,  34  can be premixed into a single ampoule and dispensed simultaneously. In one form of the invention, it is possible to introduce the ethanol first, then agitate the mixing syringe  26  and then follow with the calcium chloride, but the introduction of both simultaneously to the plasma are optimally combined, followed by brief agitation. 
     Once the ethanol and calcium chloride have been introduced into the mixing syringe  26 , the valve  24  is reoriented so that the mixing syringe  26  is isolated. The contents are briefly agitated and allowed to incubate for about 20 minutes. Prior to pushing the contents out of the mixing syringe  26 , the valve  24  is reoriented as shown in FIG. 4 after which the plunger  28  is moved in the direction of the arrow B of FIG.  4 . Because the valve  24  is now set to allow communication to the thrombin dispensing syringe  42 , the contents within the mixing syringe  26  will be transferred from the mixing syringe  26  to the dispensing syringe  42 . More specifically, the manifold  22  includes a recess within which a filter  44  is provided in the flow path between the mixing syringe  26  and the thrombin dispensing syringe  42 . Particulate matter will be retained within the filter  44  prior to delivery of the thrombin to the dispensing syringe  42 . Note that as fluid enters the dispensing syringe  42 , the dispensing syringe plunger  46  moves in a direction opposite arrow B. 
     Referring back to FIG. 1, attention is now directed to the clotting and adhesive protein processing unit  60 . All of the plasma not diverted to the thrombin processing unit  40  is admitted to an interior chamber  62  of the clotting and adhesive protein processing unit  60 . The clotting and adhesive protein processing unit  60  is manipulated by heat exchange and rotation so that all clotting and adhesive proteins extracted from the plasma will sediment at a nose  64  of the bag  62  for subsequent extraction by means of a clotting and adhesive protein dispensing syringe  66  contained in a sterile pouch  68 . Once the thrombin has been loaded into the dispensing syringe  42 , and the clotting and adhesive proteins have been loaded into the clotting and adhesive dispensing syringe  66 , the two syringes can be decoupled from the processing set  10  and ganged together for spraying or line and dot application. Mixing the thrombin with the clotting and adhesive proteins forms the biological glue. 
     Both dispensing syringes should be stored at or below 4° C. prior to usage. 
     Turning to FIG. 5, a graph is shown which illustrates how ethanol concentrations alter the life span of fast clotting thrombin where the calcium chloride content is held constant at point 0.023 μm. Note that at approximately 13.6% ethanol, its life span is shown to have been optimized and extend at least 240 minutes while its clotting time is substantially constant at under 5 seconds. The range between 8% and 18%, however, has utility. 
     FIG. 6 varies the calcium chloride concentration in the thrombin while the ethanol is held constant at 13.6%. As shown, the thrombin life span where the calcium chloride concentration is at 0.023 μm of 250 mM calcium chloride appears optimized and extends to 360 minutes while maintaining a clot time under 5 seconds. The range between 0.011 μm of 125 mM and 0.045 μm of 500 mM, however, has utility. 
     FIG. 7 reflects the differences in processing the thrombin where the thrombin mixing syringe  26  is formed from glass versus plastic. As can be shown, the speed of clotting is held to close to 5 seconds or less with a life span of 60 to 240 minutes in glass. 
     FIG. 8 reflects the effect of using ethanol at 13.6% and calcium chloride at 0.023 μm to reduce proteins which alter the clot time of the thrombin as compared to the original plasma. As can be seen in this graph, the major interfering proteins are so efficiently removed, that the clotting time of the thrombin is not only enhanced, but held substantially stable and constant. 
     FIG. 9 shows in greater detail than that which is shown in FIGS. 5 and 6 regarding the measured clot time as a function of life span for the optimized thrombin preparation, having been treated by 13.6% ethanol and 0.023 μm calcium chloride. As shown, the life span extends to 360 minutes and the clot time varies from 3 to 4 seconds. 
     FIG. 10 shows the effect of saline solution of the thrombin preparation optimized as in FIG. 9 with an ethanol concentration of 13.6% and a calcium chloride concentration of 0.023 μm as a function of life span. When the thrombin has been diluted 1 to 1.5 with saline, the clot time has been extended from just above 20 seconds to just less than 30 seconds, and has a life span of up to 150 minutes. 
     Referring to FIG. 11, there shown is the benefit in allowing the thrombin contained in the mixing syringe  26  to reside therein after agitation for almost 20 minutes in order to assure the effectiveness of the filtration step in removing particulate matter for subsequent utilization. The time span for conversation and activation allows enough particulate matter to be removed by the filter to optimize the use of the thrombin later in a narrow orificed dispenser, such as a sprayer or expressing through a thin tube. 
     FIG. 12 provides a prior art comparison of the activity of thrombin sourced from Bovine blood plasma as it relates to the speed of clotting, showing that autologous thrombin derived from this invention provides a clotting speed equivalent to 100 iu/ml of Bovine thrombin. 
     Moreover, having thus described the invention, it should be apparent that numerous structural modifications and adaptations may be resorted to without departing from the scope and fair meaning of the instant invention as set forth hereinabove and as described hereinbelow by the claims.